AR065904A1 - Heterociclos como antagonistas de orexina - Google Patents
Heterociclos como antagonistas de orexinaInfo
- Publication number
- AR065904A1 AR065904A1 ARP080101356A ARP080101356A AR065904A1 AR 065904 A1 AR065904 A1 AR 065904A1 AR P080101356 A ARP080101356 A AR P080101356A AR P080101356 A ARP080101356 A AR P080101356A AR 065904 A1 AR065904 A1 AR 065904A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- lower alkyl
- compounds
- lower alkoxy
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a compuestos de la formula 1 en la que R1 y R2 son con independencia entre sí hidrogeno o alquilo inferior; R3 con independencia del numero de sustituyentes es hidrogeno, halogeno, alquilo inferior, alquilo inferior sustituidopor halogeno, alcoxi inferior o alcoxi inferior sustituido por halogeno; R4 es halogeno, alquilo inferior, alquilo inferior sustituido por halogeno, alcoxi inferior o alcoxi inferior sustituido por halogeno; hetarilo es un anillo heteroaromático quetiene uno o dos ciclos, está conectado a los átomos de carbono del resto piperidina y se elige entre el grupo formado por el grupo de formulas (2) o a las sales de adicion de ácido farmacéuticamente idoneas, los enantiomeros opticamente puros, losracematos o mezclas diastereoméricas del mismo. Se ha encontrado que los compuestos de la formula 1 son antagonistas de receptor de orexina y los compuestos en cuestion pueden ser utiles para el tratamiento de trastornos, en los que intervienen losmecanismos de la orexina, por ejemplo los trastornos del sueno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07105596 | 2007-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065904A1 true AR065904A1 (es) | 2009-07-08 |
Family
ID=39469467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101356A AR065904A1 (es) | 2007-04-04 | 2008-04-01 | Heterociclos como antagonistas de orexina |
Country Status (16)
Country | Link |
---|---|
US (1) | US8067598B2 (es) |
EP (1) | EP2144906B1 (es) |
JP (1) | JP2010523518A (es) |
KR (1) | KR101158976B1 (es) |
CN (1) | CN101646668A (es) |
AR (1) | AR065904A1 (es) |
AT (1) | ATE512963T1 (es) |
AU (1) | AU2008235528B2 (es) |
CA (1) | CA2681163A1 (es) |
CL (1) | CL2008000957A1 (es) |
ES (1) | ES2365444T3 (es) |
IL (1) | IL200781A0 (es) |
MX (1) | MX2009010727A (es) |
PE (1) | PE20081900A1 (es) |
TW (1) | TW200845973A (es) |
WO (1) | WO2008122513A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011005636A1 (en) * | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
WO2011061318A1 (en) | 2009-11-23 | 2011-05-26 | N.V. Organon | Heterocylic compounds as antagonists of the orexin receptors |
US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
NZ628491A (en) | 2012-02-07 | 2016-06-24 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
ES2901418T3 (es) | 2014-08-13 | 2022-03-22 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
PT3414241T (pt) | 2016-02-12 | 2022-07-29 | Astrazeneca Ab | Piperidinas substituídas por halo como moduladores de recetores de oxerina |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0109200B8 (pt) * | 2000-03-14 | 2021-05-25 | Actelion Pharmaceuticals Ltd | compostos e composições farmacêuticas |
WO2002051232A2 (en) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
JP3876872B2 (ja) * | 2002-10-15 | 2007-02-07 | ソニーケミカル&インフォメーションデバイス株式会社 | エレクトロルミネスセンスポリマー、ビスフルオレニルシラン化合物及び有機el素子 |
KR20050114242A (ko) * | 2003-03-26 | 2005-12-05 | 액테리온 파마슈티칼 리미티드 | 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체 |
NZ550216A (en) | 2004-03-01 | 2009-08-28 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
EA015256B1 (ru) * | 2006-03-15 | 2011-06-30 | Актелион Фармасьютикалз Лтд. | Производные тетрагидроизохинолина для повышения функции памяти |
DE602007012072D1 (de) * | 2006-04-26 | 2011-03-03 | Actelion Pharmaceuticals Ltd | Orantagonisten |
-
2008
- 2008-03-26 WO PCT/EP2008/053545 patent/WO2008122513A1/en active Application Filing
- 2008-03-26 ES ES08718218T patent/ES2365444T3/es active Active
- 2008-03-26 JP JP2010501480A patent/JP2010523518A/ja not_active Ceased
- 2008-03-26 MX MX2009010727A patent/MX2009010727A/es active IP Right Grant
- 2008-03-26 KR KR1020097020475A patent/KR101158976B1/ko not_active IP Right Cessation
- 2008-03-26 EP EP08718218A patent/EP2144906B1/en not_active Not-in-force
- 2008-03-26 CA CA002681163A patent/CA2681163A1/en not_active Abandoned
- 2008-03-26 CN CN200880010269A patent/CN101646668A/zh active Pending
- 2008-03-26 AT AT08718218T patent/ATE512963T1/de active
- 2008-03-26 AU AU2008235528A patent/AU2008235528B2/en not_active Ceased
- 2008-03-27 US US12/056,324 patent/US8067598B2/en not_active Expired - Fee Related
- 2008-04-01 AR ARP080101356A patent/AR065904A1/es unknown
- 2008-04-01 TW TW097111894A patent/TW200845973A/zh unknown
- 2008-04-02 CL CL200800957A patent/CL2008000957A1/es unknown
- 2008-04-03 PE PE2008000605A patent/PE20081900A1/es not_active Application Discontinuation
-
2009
- 2009-09-07 IL IL200781A patent/IL200781A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2365444T3 (es) | 2011-10-05 |
IL200781A0 (en) | 2010-05-17 |
US20080249125A1 (en) | 2008-10-09 |
CN101646668A (zh) | 2010-02-10 |
AU2008235528A1 (en) | 2008-10-16 |
AU2008235528B2 (en) | 2012-11-08 |
TW200845973A (en) | 2008-12-01 |
PE20081900A1 (es) | 2009-01-26 |
KR101158976B1 (ko) | 2012-06-21 |
MX2009010727A (es) | 2009-10-26 |
CA2681163A1 (en) | 2008-10-16 |
EP2144906A1 (en) | 2010-01-20 |
US8067598B2 (en) | 2011-11-29 |
EP2144906B1 (en) | 2011-06-15 |
ATE512963T1 (de) | 2011-07-15 |
CL2008000957A1 (es) | 2008-10-10 |
WO2008122513A1 (en) | 2008-10-16 |
KR20090127313A (ko) | 2009-12-10 |
JP2010523518A (ja) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065904A1 (es) | Heterociclos como antagonistas de orexina | |
AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
CO6321153A2 (es) | Derivados de cromeno y cromano y sus usos | |
AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
AR069849A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
CO5721001A2 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
PE20140934A1 (es) | Derivados de pirazol | |
PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR071925A1 (es) | Malonamidas como antagonistas de orexina | |
UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
PE20080068A1 (es) | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora | |
AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
PE20140968A1 (es) | Derivados de benzamida sustituida | |
AR072518A1 (es) | Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met." | |
PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |